$CYTK
CYTOKINETICS INC

2017 Q1 Form 10-K Financial Statement

#000119312517071866 Filed on March 06, 2017

View on sec.gov

Income Statement

Concept 2017 Q1 2016 2015 Q4
Revenue $4.153M $106.4M $9.757M
YoY Change -50.68% 271.3% -55.16%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $8.120M $27.80M $5.530M
YoY Change 18.71% 41.12% 21.27%
% of Gross Profit
Research & Development $19.29M $59.90M $13.25M
YoY Change 42.52% 29.09% 50.91%
% of Gross Profit
Depreciation & Amortization $421.0K $741.0K $150.0K
YoY Change 147.65% 25.81% 7.14%
% of Gross Profit
Operating Expenses $27.40M $87.72M $18.78M
YoY Change 34.5% 32.78% 40.78%
Operating Profit -$23.25M $18.69M
YoY Change 94.5% -149.96%
Interest Expense $745.0K $2.698M -$210.0K
YoY Change 32.33% 906.72% -1150.0%
% of Operating Profit 14.44%
Other Income/Expense, Net $436.0K $464.0K
YoY Change 603.23% 166.67%
Pretax Income -$25.87M $16.45M -$9.230M
YoY Change 107.68% -143.87% -209.36%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income 0.0%
Net Earnings -$25.87M $16.45M -$9.229M
YoY Change 107.68% -143.87% -209.31%
Net Earnings / Revenue -622.85% 15.46% -94.59%
Basic Earnings Per Share $0.41
Diluted Earnings Per Share -$555.6K $0.39 -$236.1K
COMMON SHARES
Basic Shares Outstanding 41.73M shares 39.94M 38.85M shares
Diluted Shares Outstanding 42.56M

Balance Sheet

Concept 2017 Q1 2016 2015 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $206.6M $156.2M $111.4M
YoY Change 99.72% 40.22% 33.9%
Cash & Equivalents $49.36M $66.90M $65.08M
Short-Term Investments $157.2M $89.40M $46.37M
Other Short-Term Assets $3.600M $2.200M $1.400M
YoY Change 33.33% 57.14% 11.38%
Inventory
Prepaid Expenses
Receivables $900.0K $0.00 $0.00
Other Receivables $0.00 $200.0K $200.0K
Total Short-Term Assets $211.0M $158.6M $113.1M
YoY Change 98.86% 40.23% -13.75%
LONG-TERM ASSETS
Property, Plant & Equipment $3.488M $3.600M $1.751M
YoY Change 98.18% 100.0% 6.96%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $50.60M $7.700M $200.0K
YoY Change 892.16% 3750.0%
Other Assets $241.0K $200.0K $200.0K
YoY Change 20.5% 0.0% 0.0%
Total Long-Term Assets $54.35M $11.50M $2.130M
YoY Change 665.51% 447.62% 15.95%
TOTAL ASSETS
Total Short-Term Assets $211.0M $158.6M $113.1M
Total Long-Term Assets $54.35M $11.50M $2.130M
Total Assets $265.4M $170.1M $115.2M
YoY Change 134.39% 47.66% -13.33%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.042M $4.200M $2.238M
YoY Change 456.12% 90.91% 64.44%
Accrued Expenses $17.50M $18.00M $8.421M
YoY Change 122.2% 114.29% 55.94%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $4.825M $2.500M $0.00
YoY Change
Total Short-Term Liabilities $36.80M $33.30M $31.65M
YoY Change 49.07% 5.38% 32.67%
LONG-TERM LIABILITIES
Long-Term Debt $25.20M $27.40M $14.64M
YoY Change -14.49% 87.67%
Other Long-Term Liabilities $108.0M $15.10M $400.0K
YoY Change 8900.0% 3675.0% -97.65%
Total Long-Term Liabilities $25.20M $42.50M $14.64M
YoY Change -14.49% 183.33%
TOTAL LIABILITIES
Total Short-Term Liabilities $36.80M $33.30M $31.65M
Total Long-Term Liabilities $25.20M $42.50M $14.64M
Total Liabilities $170.0M $75.80M $46.65M
YoY Change 207.33% 62.66% 14.04%
SHAREHOLDERS EQUITY
Retained Earnings -$544.2M -$534.7M
YoY Change -0.56% 7.54%
Common Stock $639.6M $603.2M
YoY Change 5.72% 2.35%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $95.38M $94.40M $68.59M
YoY Change
Total Liabilities & Shareholders Equity $265.4M $170.1M $115.2M
YoY Change 134.39% 47.66% -13.33%

Cashflow Statement

Concept 2017 Q1 2016 2015 Q4
OPERATING ACTIVITIES
Net Income -$25.87M $16.45M -$9.229M
YoY Change 107.68% -143.87% -209.31%
Depreciation, Depletion And Amortization $421.0K $741.0K $150.0K
YoY Change 147.65% 25.81% 7.14%
Cash From Operating Activities -$20.94M $36.98M -$9.950M
YoY Change 19.59% 657.79% 22.39%
INVESTING ACTIVITIES
Capital Expenditures $1.388M $1.596M -$200.0K
YoY Change 230.48% 183.99% -16.67%
Acquisitions
YoY Change
Other Investing Activities -$110.9M -$50.48M $25.62M
YoY Change 461.85% -403.55% 291.15%
Cash From Investing Activities -$112.3M -$52.08M $25.41M
YoY Change 457.04% -424.28% 303.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $17.36M $0.00
YoY Change -100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 115.7M 16.89M 23.65M
YoY Change 678.8% -29.39% 159.04%
NET CHANGE
Cash From Operating Activities -20.94M 36.98M -9.950M
Cash From Investing Activities -112.3M -52.08M 25.41M
Cash From Financing Activities 115.7M 16.89M 23.65M
Net Change In Cash -17.51M 1.790M 39.11M
YoY Change -23.24% -96.01% 435.75%
FREE CASH FLOW
Cash From Operating Activities -$20.94M $36.98M -$9.950M
Capital Expenditures $1.388M $1.596M -$200.0K
Free Cash Flow -$22.33M $35.38M -$9.750M
YoY Change 24.53% 719.45% 23.57%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q3 cytk Potential Milestone Payments Upon Achievement Of Milestone
PotentialMilestonePaymentsUponAchievementOfMilestone
500000
CY2017Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
41729549 shares
CY2012Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9320176 shares
CY2012Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
7894704 shares
CY2012Q2 us-gaap Share Price
SharePrice
4.56
CY2016Q2 dei Entity Public Float
EntityPublicFloat
375500000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
20158000
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
54442000
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
15.15
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
2161829 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2449365 shares
CY2014Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
204900000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
20215000
CY2014Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
6217000
CY2014Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2014Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
34543000
CY2014Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
204900000
CY2014Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
148184000
CY2014Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2015Q4 cytk Accrued Leasehold Improvements Current
AccruedLeaseholdImprovementsCurrent
0
CY2016Q4 us-gaap Available For Sale Securities Noncurrent
AvailableForSaleSecuritiesNoncurrent
7672000
CY2014Q4 us-gaap Share Price
SharePrice
8.00
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
92064000
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
12.62
CY2014Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
6274000
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
1270478 shares
CY2014Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
5100000
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3297826 shares
CY2014Q4 cytk Deferred Tax Assets Depreciation And Amortization
DeferredTaxAssetsDepreciationAndAmortization
780000
CY2014Q4 cytk Deferred Tax Assets Capitalized Research And Development
DeferredTaxAssetsCapitalizedResearchAndDevelopment
15176000
CY2015Q4 us-gaap Available For Sale Securities Noncurrent
AvailableForSaleSecuritiesNoncurrent
179000
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
-389000
CY2015Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
20842000
CY2015Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
111600000
CY2015Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
15000000
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
39581692 shares
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
39581692 shares
CY2015Q4 us-gaap Assets
Assets
115237000
CY2015Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
359000
CY2015Q4 us-gaap Accounts Receivable Related Parties Current
AccountsReceivableRelatedPartiesCurrent
12000
CY2015Q4 us-gaap Assets Current
AssetsCurrent
113107000
CY2015Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
218811000
CY2015Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
2720000
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
81500000 shares
CY2015Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
603145000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
65076000
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
40000
CY2015Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
0
CY2015Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
12899000
CY2015Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2238000
CY2015Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
20858000
CY2015Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2015Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
46366000
CY2015Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
38742000
CY2015Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
149000
CY2015Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
218811000
CY2015Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
153251000
CY2015Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8421000
CY2015Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2015Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2016Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
-472000
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
21118000
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
14639000
CY2015Q4 us-gaap Long Term Debt
LongTermDebt
14639000
CY2015Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
0
CY2015Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2015Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2015Q4 us-gaap Liabilities
Liabilities
46647000
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
115237000
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
31649000
CY2015Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
791000
CY2015Q4 us-gaap Interest Receivable
InterestReceivable
200000
CY2015Q4 us-gaap Long Term Debt Fair Value
LongTermDebtFairValue
14600000
CY2015Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
200000
CY2015Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2015Q4 us-gaap Other Employee Related Liabilities Current
OtherEmployeeRelatedLiabilitiesCurrent
1464000
CY2015Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1751000
CY2015Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
22593000
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
68590000
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
10.94
CY2015Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
6715000
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-534744000
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
2816010 shares
CY2015Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1653000
CY2015Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
5500000
CY2015Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4078159 shares
CY2015Q4 cytk Deferred Tax Assets Depreciation And Amortization
DeferredTaxAssetsDepreciationAndAmortization
769000
CY2015Q4 cytk Deferred Tax Assets Capitalized Research And Development
DeferredTaxAssetsCapitalizedResearchAndDevelopment
13150000
CY2015Q4 cytk Debt Instrument Accretion Of Final Exit Fee
DebtInstrumentAccretionOfFinalExitFee
28000
CY2015Q4 cytk Accrued Clinical And Preclinical Costs Current
AccruedClinicalAndPreclinicalCostsCurrent
3446000
CY2015Q4 cytk Deferred Rent Credit And Interest Payable Current
DeferredRentCreditAndInterestPayableCurrent
132000
CY2016Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
163900000
CY2016Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
30000000
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
40646595 shares
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
40646595 shares
CY2016Q4 us-gaap Assets
Assets
170142000
CY2016Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
142000
CY2016Q4 us-gaap Accounts Receivable Related Parties Current
AccountsReceivableRelatedPartiesCurrent
24000
CY2016Q4 us-gaap Assets Current
AssetsCurrent
158633000
CY2016Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
216658000
CY2016Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
3800000
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
163000000 shares
CY2016Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
612474000
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
66874000
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
41000
CY2016Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
15000000
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
10258000
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4236000
CY2016Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
8060000
CY2016Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2016Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
89375000
CY2016Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
4200000 shares
CY2016Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
46998000
CY2016Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
0
CY2016Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
137000
CY2016Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
216658000
CY2016Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
146961000
CY2016Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
18047000
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
5563000
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2016Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
27381000
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
0
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
0
CY2016Q4 us-gaap Long Term Debt
LongTermDebt
29881000
CY2016Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
2500000
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
3703000
CY2016Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2016Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2016Q4 us-gaap Liabilities
Liabilities
75781000
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
170142000
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
33258000
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
0
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1595000
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
0
CY2016Q4 us-gaap Interest Receivable
InterestReceivable
200000
CY2016Q4 us-gaap Long Term Debt Fair Value
LongTermDebtFairValue
29900000
CY2016Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
200000
CY2016Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
21294000
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
1860000
CY2016Q4 us-gaap Other Employee Related Liabilities Current
OtherEmployeeRelatedLiabilitiesCurrent
1888000
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3637000
CY2016Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
24755000
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
10.24
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
94361000
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.27
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3364286 shares
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
21075000
CY2016Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
7565000
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-518291000
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
1588300 shares
CY2016Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2360000
CY2016Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
6300000
CY2016Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2016Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
12771000
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
5147387 shares
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
9.29
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5192813 shares
CY2016Q4 cytk Number Of Financial Institutions
NumberOfFinancialInstitutions
3 Financial_Institution
CY2016Q4 cytk Deferred Tax Assets Depreciation And Amortization
DeferredTaxAssetsDepreciationAndAmortization
766000
CY2016Q4 cytk Deferred Tax Assets Capitalized Research And Development
DeferredTaxAssetsCapitalizedResearchAndDevelopment
11675000
CY2016Q4 cytk Debt Instrument Accretion Of Final Exit Fee
DebtInstrumentAccretionOfFinalExitFee
353000
CY2016Q4 cytk Accrued Clinical And Preclinical Costs Current
AccruedClinicalAndPreclinicalCostsCurrent
10092000
CY2016Q4 cytk Deferred Rent Credit And Interest Payable Current
DeferredRentCreditAndInterestPayableCurrent
415000
CY2016Q4 cytk Accrued Leasehold Improvements Current
AccruedLeaseholdImprovementsCurrent
672000
CY2012Q2 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
60000000
CY2012Q2 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
4000000
CY2012Q2 cytk Proceeds From Issuance Or Sale Of Stock And Warrant
ProceedsFromIssuanceOrSaleOfStockAndWarrant
56000000
CY2016Q2 us-gaap Litigation Settlement Amount
LitigationSettlementAmount
4500000
CY2016Q3 cytk Percentage Of Shared Costs
PercentageOfSharedCosts
0.25 pure
CY2015Q3 cytk Research Development Grant
ResearchDevelopmentGrant
1500000
CY2016Q4 cytk Number Of Issued Shares Of Common Stock Related To Exercise Of Warrants
NumberOfIssuedSharesOfCommonStockRelatedToExerciseOfWarrants
4104966 shares
CY2014 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0
CY2014 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0
CY2014 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10067000 shares
CY2014 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3330000
CY2014 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
57000
CY2014 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.01 pure
CY2014 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3330000
CY2014 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
0
CY2014 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
0
CY2014 us-gaap Gain On Sale Of Investments
GainOnSaleOfInvestments
6000
CY2014 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
17268000
CY2014 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.41
CY2014 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
96000
CY2014 us-gaap Depreciation
Depreciation
500000
CY2014 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
490000
CY2014 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.41
CY2014 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14657000
CY2014 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.00 pure
CY2014 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
0
CY2014 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
300000
CY2014 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.00 pure
CY2014 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2014 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.05 pure
CY2014 us-gaap Revenues
Revenues
46940000
CY2014 us-gaap Interest Paid
InterestPaid
0
CY2014 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
3338000
CY2014 us-gaap Incremental Common Shares Attributable To Contingently Issuable Shares
IncrementalCommonSharesAttributableToContingentlyIssuableShares
0 shares
CY2014 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
108000
CY2014 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
104098000
CY2014 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-2865000
CY2014 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-2178000
CY2014 us-gaap Operating Expenses
OperatingExpenses
61694000
CY2014 us-gaap Net Income Loss
NetIncomeLoss
-14646000
CY2014 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-14646000
CY2014 us-gaap Increase Decrease In Due From Related Parties Current
IncreaseDecreaseInDueFromRelatedPartiesCurrent
46641000
CY2014 us-gaap Interest Expense
InterestExpense
0
CY2014 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-4049000
CY2014 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-11000
CY2014 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
107043000
CY2014 us-gaap Incremental Common Shares Attributable To Equity Unit Purchase Agreements
IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements
0 shares
CY2014 us-gaap License And Services Revenue
LicenseAndServicesRevenue
9836000
CY2014 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-14646000
CY2014 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
0
CY2014 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-274000
CY2014 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-11000
CY2014 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0 shares
CY2014 us-gaap Operating Income Loss
OperatingIncomeLoss
-14754000
CY2014 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
48949000
CY2014 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0
CY2014 us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
0
CY2014 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
1000
CY2014 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
2800000
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
944831 shares
CY2014 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
67000
CY2014 us-gaap Revenue From Grants
RevenueFromGrants
75000
CY2014 cytk Increase Decrease In Noncash Or Part Noncash Acquisition Fixed Assets Acquired Through Accrued Liabilities
IncreaseDecreaseInNoncashOrPartNoncashAcquisitionFixedAssetsAcquiredThroughAccruedLiabilities
27000
CY2014 cytk License Revenues From Related Parties
LicenseRevenuesFromRelatedParties
0
CY2014 us-gaap Share Based Compensation
ShareBasedCompensation
3330000
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
39.74
CY2014 cytk Stock Issued During Period Value New Issues To Collaborative Partner
StockIssuedDuringPeriodValueNewIssuesToCollaborativePartner
9102000
CY2014 cytk Effective Income Tax Rate Reconciliation State Apportionment
EffectiveIncomeTaxRateReconciliationStateApportionment
0.28 pure
CY2014 cytk Proceeds And Payments From Stock Based Award And Warrants Net Of Issuance Costs
ProceedsAndPaymentsFromStockBasedAwardAndWarrantsNetOfIssuanceCosts
22000
CY2014 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
17399000
CY2014 us-gaap Investment Income Interest
InvestmentIncomeInterest
101000
CY2014 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
1000000
CY2014 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
0 shares
CY2014 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2014 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-44843000
CY2014 us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
0
CY2014 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1104000
CY2014 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
48971000
CY2014 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0
CY2014 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.07 pure
CY2014 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
35709000 shares
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
944831 shares
CY2014 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
8.80
CY2014 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
95980 shares
CY2014 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
6.00
CY2014 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35709000 shares
CY2014 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2000
CY2014 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
44426000
CY2014 cytk Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice
6.00
CY2014 cytk Effective Income Tax Rate Reconciliation Net Operating Loss Expiration
EffectiveIncomeTaxRateReconciliationNetOperatingLossExpiration
0.02 pure
CY2014 cytk Stock Issued During Period Value Exercise Of Warrants
StockIssuedDuringPeriodValueExerciseOfWarrants
6000
CY2014 cytk Effective Income Tax Rate Reconciliation Deferred Tax Assets Utilized Not Benefited
EffectiveIncomeTaxRateReconciliationDeferredTaxAssetsUtilizedNotBenefited
0.07 pure
CY2014 cytk Stock Issued During Period Value Securities Purchase Agreement
StockIssuedDuringPeriodValueSecuritiesPurchaseAgreement
37492000
CY2014 cytk Share Based Compensation Arrangement By Share Based Payment Shares Available For Grant Award Options Exercised In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentSharesAvailableForGrantAwardOptionsExercisedInPeriodGross
0 shares
CY2014 cytk Issuance Of Common Stock To Collaborative Partner Issuance Costs
IssuanceOfCommonStockToCollaborativePartnerIssuanceCosts
8000
CY2014 cytk Increase Decrease In Noncash Or Part Noncash Acquisition Fixed Assets Acquired Through Accounts Payable
IncreaseDecreaseInNoncashOrPartNoncashAcquisitionFixedAssetsAcquiredThroughAccountsPayable
170000
CY2014 cytk Issuance Of Common Stock To Collaborative Partner For Cash Per Share
IssuanceOfCommonStockToCollaborativePartnerForCashPerShare
4.90
CY2014 cytk Issuance Of Common Stock Employee Stock Purchase Plan Price Per Share
IssuanceOfCommonStockEmployeeStockPurchasePlanPricePerShare
3.38
CY2014 cytk Research And Development Revenues From Related Parties
ResearchAndDevelopmentRevenuesFromRelatedParties
19538000
CY2014 cytk Shares Available For Grant Of Options Or Awards Options Forfeited Expired
SharesAvailableForGrantOfOptionsOrAwardsOptionsForfeitedExpired
95980 shares
CY2014 cytk Debt Discount Netted Against Proceeds From Long Term Debt Recorded In Equity
DebtDiscountNettedAgainstProceedsFromLongTermDebtRecordedInEquity
0
CY2014 cytk Noncash Interest Expense
NoncashInterestExpense
0
CY2014 cytk Research And Development Grant And Other Revenues
ResearchAndDevelopmentGrantAndOtherRevenues
17566000
CY2014 cytk Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate Due To Pre Tax Income Loss
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateDueToPreTaxIncomeLoss
-0.34 pure
CY2015 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0
CY2015 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0
CY2015 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11249000 shares
CY2015 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4567000
CY2015 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
44861000
CY2015 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.00 pure
CY2015 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
282000
CY2015 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4567000
CY2015 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
0
CY2015 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
0
CY2015 us-gaap Gain On Sale Of Investments
GainOnSaleOfInvestments
3000
CY2015 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
19667000
CY2015 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.97
CY2015 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
144000
CY2015 us-gaap Depreciation
Depreciation
600000
CY2015 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
589000
CY2015 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.97
CY2015 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-37348000
CY2015 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.00 pure
CY2015 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
0
CY2015 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
400000
CY2015 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.00 pure
CY2015 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2015 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.02 pure
CY2015 us-gaap Revenues
Revenues
28658000
CY2015 us-gaap Interest Paid
InterestPaid
94000
CY2015 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
3297000
CY2015 us-gaap Incremental Common Shares Attributable To Contingently Issuable Shares
IncrementalCommonSharesAttributableToContingentlyIssuableShares
0 shares
CY2015 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
174000
CY2015 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
132190000
CY2015 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2995000
CY2015 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
755000
CY2015 us-gaap Operating Expenses
OperatingExpenses
66065000
CY2015 us-gaap Net Income Loss
NetIncomeLoss
-37501000
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-37501000
CY2015 us-gaap Increase Decrease In Due From Related Parties Current
IncreaseDecreaseInDueFromRelatedPartiesCurrent
-46634000
CY2015 us-gaap Interest Expense
InterestExpense
268000
CY2015 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
16063000
CY2015 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
153000
CY2015 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
115566000
CY2015 us-gaap Incremental Common Shares Attributable To Equity Unit Purchase Agreements
IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements
0 shares
CY2015 us-gaap License And Services Revenue
LicenseAndServicesRevenue
0
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-37501000
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
0
CY2015 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
396000
CY2015 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
153000
CY2015 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0 shares
CY2015 us-gaap Operating Income Loss
OperatingIncomeLoss
-37407000
CY2015 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
23915000
CY2015 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
18000
CY2015 us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
41000
CY2015 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
1000
CY2015 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-12742000
CY2015 us-gaap Investment Income Interest
InvestmentIncomeInterest
156000
CY2015 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
13900000
CY2015 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
0 shares
CY2015 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2015 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
4883000
CY2015 us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
14890000
CY2015 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
562000
CY2015 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
8673000
CY2015 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
1000
CY2015 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.07 pure
CY2015 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
38814000 shares
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
1175730 shares
CY2015 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
7.62
CY2015 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
3130000 shares
CY2015 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
441000
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
326762 shares
CY2015 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
6.22
CY2015 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
38814000 shares
CY2015 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
427000
CY2015 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
46398000
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1175730 shares
CY2015 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
69000
CY2015 us-gaap Revenue From Grants
RevenueFromGrants
75000
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
0 shares
CY2015 us-gaap Share Based Compensation
ShareBasedCompensation
4567000
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
16.83
CY2015 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
0
CY2015 cytk Effective Income Tax Rate Reconciliation State Apportionment
EffectiveIncomeTaxRateReconciliationStateApportionment
0.00 pure
CY2015 cytk Proceeds And Payments From Stock Based Award And Warrants Net Of Issuance Costs
ProceedsAndPaymentsFromStockBasedAwardAndWarrantsNetOfIssuanceCosts
-352000
CY2015 cytk Increase Decrease In Noncash Or Part Noncash Acquisition Fixed Assets Acquired Through Accrued Liabilities
IncreaseDecreaseInNoncashOrPartNoncashAcquisitionFixedAssetsAcquiredThroughAccruedLiabilities
-2000
CY2015 cytk License Revenues From Related Parties
LicenseRevenuesFromRelatedParties
13918000
CY2015 cytk Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice
6.22
CY2015 cytk Effective Income Tax Rate Reconciliation Net Operating Loss Expiration
EffectiveIncomeTaxRateReconciliationNetOperatingLossExpiration
0.02 pure
CY2015 cytk Stock Issued During Period Value Exercise Of Warrants
StockIssuedDuringPeriodValueExerciseOfWarrants
0
CY2015 cytk Effective Income Tax Rate Reconciliation Deferred Tax Assets Utilized Not Benefited
EffectiveIncomeTaxRateReconciliationDeferredTaxAssetsUtilizedNotBenefited
0.37 pure
CY2015 cytk Share Based Compensation Arrangement By Share Based Payment Shares Available For Grant Award Options Exercised In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentSharesAvailableForGrantAwardOptionsExercisedInPeriodGross
0 shares
CY2015 cytk Increase Decrease In Noncash Or Part Noncash Acquisition Fixed Assets Acquired Through Accounts Payable
IncreaseDecreaseInNoncashOrPartNoncashAcquisitionFixedAssetsAcquiredThroughAccountsPayable
-147000
CY2015 cytk Issuance Of Common Stock Employee Stock Purchase Plan Price Per Share
IssuanceOfCommonStockEmployeeStockPurchasePlanPricePerShare
3.24
CY2015 cytk Research And Development Revenues From Related Parties
ResearchAndDevelopmentRevenuesFromRelatedParties
14665000
CY2015 cytk Shares Available For Grant Of Options Or Awards Options Forfeited Expired
SharesAvailableForGrantOfOptionsOrAwardsOptionsForfeitedExpired
326762 shares
CY2015 cytk Debt Discount Netted Against Proceeds From Long Term Debt Recorded In Equity
DebtDiscountNettedAgainstProceedsFromLongTermDebtRecordedInEquity
282000
CY2015 cytk Noncash Interest Expense
NoncashInterestExpense
3000
CY2015 cytk Research And Development Grant And Other Revenues
ResearchAndDevelopmentGrantAndOtherRevenues
75000
CY2015 cytk Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate Due To Pre Tax Income Loss
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateDueToPreTaxIncomeLoss
-0.34 pure
CY2016 dei Entity Registrant Name
EntityRegistrantName
CYTOKINETICS INC
CY2016 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0
CY2016 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0
CY2016 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3688000 shares
CY2016 dei Document Type
DocumentType
10-K
CY2016 dei Entity Central Index Key
EntityCentralIndexKey
0001061983
CY2016 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7146000
CY2016 dei Document Period End Date
DocumentPeriodEndDate
2016-12-31
CY2016 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
1798000
CY2016 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.02 pure
CY2016 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
288000
CY2016 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2016 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7146000
CY2016 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
0
CY2016 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
0
CY2016 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2016
CY2016 dei Amendment Flag
AmendmentFlag
false
CY2016 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2016 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2016 us-gaap Gain On Sale Of Investments
GainOnSaleOfInvestments
0
CY2016 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
27823000
CY2016 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.41
CY2016 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
135000
CY2016 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 2%; MARGIN-TOP: 18pt"> <b><i>Concentration of Credit Risk and Other Risks and Uncertainties</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%" align="justify">Financial instruments that potentially subject the Company to concentrations of risk consist principally of cash and cash equivalents, investments, long term debt and accounts receivable.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%" align="justify">The Company&#x2019;s cash, cash equivalents and investments are invested in deposits with three major financial institutions in the United States.&#xA0;Deposits in these banks may exceed the amount of insurance provided on such deposits. The Company has not experienced any realized losses on its deposits of cash, cash equivalents or investments.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%" align="justify">The economic turmoil in the United States in recent years, the extraordinary volatility in the stock markets and other current negative macroeconomic indicators could negatively impact the Company&#x2019;s ability to raise the funds necessary to support its business and may materially adversely affect its business, operating results and financial condition.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%" align="justify">The Company performs an ongoing credit evaluation of its strategic partners&#x2019; financial conditions and generally does not require collateral to secure accounts receivable from its strategic partners. The Company&#x2019;s exposure to credit risk associated with <font style="WHITE-SPACE: nowrap">non-payment</font> will be affected principally by conditions or occurrences within Amgen Inc. (&#x201C;Amgen&#x201D;) and Astellas Pharma Inc. (&#x201C;Astellas&#x201D;), its strategic partners. Approximately 26%, 9% and 10% of total revenues for the years ended December&#xA0;31, 2016, 2015 and 2014, respectively, were derived from Amgen. There were no accounts receivable due from Amgen at December&#xA0;31, 2016 and 2015. Approximately 73%, 91% and 90% of total revenues for the years ended December&#xA0;31, 2016, 2015 and 2014, respectively, were derived from Astellas. There were no accounts receivable due from Astellas at December&#xA0;31, 2016 and 2015. See also Note&#xA0;7, &#x201C;Related Party Transactions,&#x201D; regarding the collaboration agreements with Amgen and Astellas.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%" align="justify">Drug candidates developed by the Company may require approvals or clearances from the U.S.&#xA0;Food and Drug Administration (&#x201C;FDA&#x201D;) or international regulatory agencies prior to commercial sales. There can be no assurance that the Company&#x2019;s drug candidates will receive any of the required approvals or clearances. If the Company was to be denied approval or clearance or any such approval or clearance was to be delayed, it would have a material adverse impact on the Company.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%" align="justify">The Company&#x2019;s operations and employees are located in the United States. In the year ended December&#xA0;31, 2016, 27% of the Company&#x2019;s revenues were received from entities located in the United States and 73% were received from a Japanese entity. In the year ended December&#xA0;31, 2015, 9% of the Company&#x2019;s revenues were received from entities located in the United States and 91% were received from a Japanese entity. In the year ended December&#xA0;31, 2014, 10% of the Company&#x2019;s revenues were received from entities located in the United States and 90% were received from a Japanese entity.</p> </div>
CY2016 us-gaap Depreciation
Depreciation
700000
CY2016 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
741000
CY2016 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2016 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.39
CY2016 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
16441000
CY2016 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.02 pure
CY2016 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2016 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2016 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
0
CY2016 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
500000
CY2016 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.00 pure
CY2016 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2016 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.07 pure
CY2016 us-gaap Revenues
Revenues
106407000
CY2016 us-gaap Interest Paid
InterestPaid
1899000
CY2016 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
3448000
CY2016 us-gaap Incremental Common Shares Attributable To Contingently Issuable Shares
IncrementalCommonSharesAttributableToContingentlyIssuableShares
181000 shares
CY2016 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
464000
CY2016 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
94645000
CY2016 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
8945000
CY2016 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
1698000
CY2016 us-gaap Operating Expenses
OperatingExpenses
87720000
CY2016 us-gaap Net Income Loss
NetIncomeLoss
16453000
CY2016 us-gaap Interest Expense
InterestExpense
2698000
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
16453000
CY2016 us-gaap Increase Decrease In Due From Related Parties Current
IncreaseDecreaseInDueFromRelatedPartiesCurrent
12000
CY2016 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-52076000
CY2016 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-12000
CY2016 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
145158000
CY2016 us-gaap Incremental Common Shares Attributable To Equity Unit Purchase Agreements
IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements
9000 shares
CY2016 us-gaap License And Services Revenue
LicenseAndServicesRevenue
0
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
16453000
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
0
CY2016 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
707000
CY2016 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-12000
CY2016 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
409000 shares
CY2016 us-gaap Operating Income Loss
OperatingIncomeLoss
18687000
CY2016 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
16892000
CY2016 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
18000
CY2016 us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
63000
CY2016 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
1000
CY2016 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
2202000
CY2016 us-gaap Investment Income Interest
InvestmentIncomeInterest
449000
CY2016 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-2200000
CY2016 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
2019000 shares
CY2016 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2016 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
36982000
CY2016 us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
14996000
CY2016 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1 Segment
CY2016 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1596000
CY2016 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
CY2016 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
33000
CY2016 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 2%; MARGIN-TOP: 18pt"> <b><i>Use of Estimates</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%" align="justify">The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p> </div>
CY2016 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.32 pure
CY2016 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
42561000 shares
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
1446675 shares
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y9M29D
CY2016 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
7.10
CY2016 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
2618000 shares
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y9M29D
CY2016 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
503000
CY2016 dei Trading Symbol
TradingSymbol
CYTK
CY2016 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
59897000
CY2016 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
845000
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
257465 shares
CY2016 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
6.75
CY2016 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
39943000 shares
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1446675 shares
CY2016 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
917000
CY2016 us-gaap Revenue From Grants
RevenueFromGrants
1084000
CY2016 us-gaap Share Based Compensation
ShareBasedCompensation
7146000
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
24.25
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P6Y9M22D
CY2016 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
5000
CY2016 cytk Effective Income Tax Rate Reconciliation State Apportionment
EffectiveIncomeTaxRateReconciliationStateApportionment
-0.07 pure
CY2016 cytk Proceeds And Payments From Stock Based Award And Warrants Net Of Issuance Costs
ProceedsAndPaymentsFromStockBasedAwardAndWarrantsNetOfIssuanceCosts
-1896000
CY2016 cytk Increase Decrease In Noncash Or Part Noncash Acquisition Fixed Assets Acquired Through Accrued Liabilities
IncreaseDecreaseInNoncashOrPartNoncashAcquisitionFixedAssetsAcquiredThroughAccruedLiabilities
-747000
CY2016 cytk License Revenues From Related Parties
LicenseRevenuesFromRelatedParties
62171000
CY2016 cytk Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePrice
6.75
CY2016 cytk Effective Income Tax Rate Reconciliation Net Operating Loss Expiration
EffectiveIncomeTaxRateReconciliationNetOperatingLossExpiration
0.09 pure
CY2016 cytk Non Cancelable Lease Expiration Year
NonCancelableLeaseExpirationYear
2018
CY2016 cytk Non Cancelable Lease Additional Extension Period
NonCancelableLeaseAdditionalExtensionPeriod
P3Y
CY2016 cytk Stock Issued During Period Value Exercise Of Warrants
StockIssuedDuringPeriodValueExerciseOfWarrants
611000
CY2016 cytk Effective Income Tax Rate Reconciliation Deferred Tax Assets Utilized Not Benefited
EffectiveIncomeTaxRateReconciliationDeferredTaxAssetsUtilizedNotBenefited
-0.15 pure
CY2016 cytk Share Based Compensation Arrangement By Share Based Payment Shares Available For Grant Award Options Exercised In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentSharesAvailableForGrantAwardOptionsExercisedInPeriodGross
0 shares
CY2016 cytk Cash Requirements Term
CashRequirementsTerm
P12M
CY2016 cytk Research And Development Federal Tax Credit Carryforwards Expiration Date Year
ResearchAndDevelopmentFederalTaxCreditCarryforwardsExpirationDateYear
2021
CY2016 cytk Federal And State Net Operating Loss Relates To Stock Option Deductions
FederalAndStateNetOperatingLossRelatesToStockOptionDeductions
2000000
CY2016 cytk Percentage Of Income Tax Positions Likely To Be Realized
PercentageOfIncomeTaxPositionsLikelyToBeRealized
0.50 pure
CY2016 cytk Increase Decrease In Noncash Or Part Noncash Acquisition Fixed Assets Acquired Through Accounts Payable
IncreaseDecreaseInNoncashOrPartNoncashAcquisitionFixedAssetsAcquiredThroughAccountsPayable
-320000
CY2016 cytk Issuance Of Common Stock Employee Stock Purchase Plan Price Per Share
IssuanceOfCommonStockEmployeeStockPurchasePlanPricePerShare
7.08
CY2016 cytk Research And Development Revenues From Related Parties
ResearchAndDevelopmentRevenuesFromRelatedParties
42994000
CY2016 cytk Shares Available For Grant Of Options Or Awards Options Forfeited Expired
SharesAvailableForGrantOfOptionsOrAwardsOptionsForfeitedExpired
257465 shares
CY2016 cytk Debt Discount Netted Against Proceeds From Long Term Debt Recorded In Equity
DebtDiscountNettedAgainstProceedsFromLongTermDebtRecordedInEquity
288000
CY2016 cytk Noncash Interest Expense
NoncashInterestExpense
534000
CY2016 cytk Research And Development Grant And Other Revenues
ResearchAndDevelopmentGrantAndOtherRevenues
1242000
CY2016 cytk Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate Due To Pre Tax Income Loss
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateDueToPreTaxIncomeLoss
0.34 pure
CY2015Q1 us-gaap Sales Revenue Net
SalesRevenueNet
4414000
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
-8872000
CY2015Q1 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.23
CY2015Q2 us-gaap Sales Revenue Net
SalesRevenueNet
6542000
CY2015Q2 us-gaap Net Income Loss
NetIncomeLoss
-10551000
CY2015Q2 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.27
CY2016Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.31
CY2016Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.31
CY2016Q1 us-gaap Sales Revenue Net
SalesRevenueNet
8421000
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-12455000
CY2016Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.29
CY2016Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.29
CY2016Q2 us-gaap Sales Revenue Net
SalesRevenueNet
5802000
CY2016Q2 us-gaap Net Income Loss
NetIncomeLoss
-11611000
CY2015Q3 us-gaap Sales Revenue Net
SalesRevenueNet
7945000
CY2015Q3 us-gaap Net Income Loss
NetIncomeLoss
-8849000
CY2015Q3 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.23
CY2016Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.84
CY2016Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.77
CY2016Q3 us-gaap Sales Revenue Net
SalesRevenueNet
59047000
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
33362000
CY2015Q4 us-gaap Sales Revenue Net
SalesRevenueNet
9757000
CY2015Q4 us-gaap Net Income Loss
NetIncomeLoss
-9229000
CY2015Q4 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.24
CY2016Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.18
CY2016Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.16
CY2016Q4 us-gaap Sales Revenue Net
SalesRevenueNet
33138000
CY2016Q4 us-gaap Net Income Loss
NetIncomeLoss
7157000

Files In Submission

Name View Source Status
0001193125-17-071866-index-headers.html Edgar Link pending
0001193125-17-071866-index.html Edgar Link pending
0001193125-17-071866.txt Edgar Link pending
0001193125-17-071866-xbrl.zip Edgar Link pending
cytk-20161231.xml Edgar Link completed
cytk-20161231.xsd Edgar Link pending
cytk-20161231_cal.xml Edgar Link unprocessable
cytk-20161231_def.xml Edgar Link unprocessable
cytk-20161231_lab.xml Edgar Link unprocessable
cytk-20161231_pre.xml Edgar Link unprocessable
d307977d10k.htm Edgar Link pending
d307977dex1044.htm Edgar Link pending
d307977dex1045.htm Edgar Link pending
d307977dex231.htm Edgar Link pending
d307977dex311.htm Edgar Link pending
d307977dex312.htm Edgar Link pending
d307977dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g307977g05t81.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending